A nurse is caring for a client who is taking warfarin and reports taking several new herbal supplements. The nurse should identify that which of the following supplements is contraindicated for concurrent use with warfarin?

A. “You should take this medication once each day at bedtime.” This statement is incorrect because rifampin is typically taken on an empty stomach, either 1 hour before or 2 hours after a meal, to ensure optimal absorption. Taking it at bedtime is not a standard recommendation.
B. “You can continue to wear soft contact lenses while taking this medication.” This statement is incorrect because rifampin can cause discoloration of bodily fluids, including tears, which can stain soft contact lenses. Patients are usually advised to avoid wearing soft contact lenses during treatment.
C. “This medication will not interfere with the effectiveness of oral contraceptives.” This statement is incorrect because rifampin is known to reduce the effectiveness of oral contraceptives. Patients should be advised to use an alternative or additional form of contraception while taking rifampin.
D. “Your urine will turn orange while you are taking this medication.” This statement is correct. Rifampin commonly causes a harmless discoloration of urine, sweat, saliva, and tears to an orange or reddish color. Patients should be informed about this side effect to avoid unnecessary concern.

A. Digoxin and levothyroxine. These medications do not typically interact to cause hearing loss. Digoxin is used for heart conditions, and levothyroxine is a thyroid hormone replacement. Their interaction does not pose a risk for ototoxicity.
B. Furosemide and amikacin. This combination is known to cause ototoxicity. Furosemide is a loop diuretic, and amikacin is an aminoglycoside antibiotic. Both drugs have ototoxic potential, and their combined use increases the risk of hearing loss.
C. Losartan and atorvastatin. These medications do not typically interact to cause hearing loss. Losartan is an antihypertensive, and atorvastatin is a cholesterol-lowering agent. Their interaction does not pose a risk for ototoxicity.
D. Propranolol and raloxifene. These medications do not typically interact to cause hearing loss. Propranolol is a beta-blocker, and raloxifene is used for osteoporosis. Their interaction does not pose a risk for ototoxicity.